Начало・Списък с акции・Puma Biotechnology Inc

Puma Biotechnology Inc

Затворен

СекторЗдравеопазване

8.09 1.25

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

7.75

Максимум

8.07

Ключови измерители
By Trading Economics
Приходи	-16M -3.8M
Продажби	-31M 45M
P/E Средно за сектора	16.521 68.51
EPS	-0.04
Марж на печалбата	-8.375
Служители	179
EBITDA	-27M -196K

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	-35.9% downside

Дивиденти
By Acuity
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	20M 404M
Предишно отваряне	6.84
Предишно затваряне	8.09

Настроения в новините

By Acuity

50%

175 / 340 Класиране в Healthcare

Puma Biotechnology Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.08.2026 г., 19:56 ч. UTC

Puma Biotechnology Inc is trading higher today, benefiting from a decline in crude oil prices that eased inflation concerns. Shares earlier pulled back from a session high.

3.08.2026 г., 19:51 ч. UTC

Puma Biotechnology Inc shares are lower today, reflecting a decline since Friday. The stock saw significant volatility, initially rising before dropping sharply.

31.07.2026 г., 19:16 ч. UTC

Puma Biotechnology Inc shares are lower today, continuing a decline since Thursday's close. The stock is trading near the lower end of its one-month range.

30.07.2026 г., 18:31 ч. UTC

Puma Biotechnology Inc shares are higher as the overall market recovers from recent declines. The stock remains below its 20-day moving average.

29.07.2026 г., 18:23 ч. UTC

Puma Biotechnology Inc shares are lower amid broader market weakness as investors await the Federal Reserve's interest rate decision this afternoon.

28.07.2026 г., 18:06 ч. UTC

Puma Biotechnology shares are lower amid broader market trends, influenced by declines in Asian markets, particularly in technology sectors.

27.07.2026 г., 19:46 ч. UTC

Puma Biotechnology Inc shares are higher, reflecting broader market gains amid a significant decline in crude oil prices following geopolitical developments.

24.07.2026 г., 19:26 ч. UTC

Puma Biotechnology Inc. shares are roughly flat as no specific news emerged during Friday's trading session, fluctuating within a routine range.

23.07.2026 г., 20:06 ч. UTC

Puma Biotechnology Inc shares are higher during Thursday's session, continuing an upward trend since Wednesday's close amid no specific news identified.

22.07.2026 г., 22:51 ч. UTC

Puma Biotechnology Inc shares are trading higher in after-market hours, building on earlier gains. The stock remains above its 20-day moving average.

21.07.2026 г., 18:02 ч. UTC

Puma Biotechnology Inc shares are higher during Tuesday's session, continuing a positive trend since Monday. The stock remains above its 20-day moving average.

20.07.2026 г., 20:06 ч. UTC

Puma Biotechnology Inc shares are lower today, having reached a mid-day low of -4.46%. No specific news has been identified to explain the decline.

Сравнение с други в отрасъла

Ценова промяна

Puma Biotechnology Inc Прогноза

Ценова цел

By TipRanks

-35.9% надолу

12-месечна прогноза

Среден 5 USD -35.9%

Висок 5 USD

Нисък 5 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Puma Biotechnology Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Puma Biotechnology Inc през последните 3 месеца.

Настроение

By Acuity

175 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.